Jeremy Morgan, APRN
Family · Oklahoma City, OKNPI 1588148571
Payments from drug & device makers
Across 959 payments — averaging $66.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$20K
- Amgen$12K
- ANI Pharmaceuticals, Inc.$7K
- AstraZeneca$6K
- Johnson & Johnson$5K
- Kyowa Kirin, Inc.$3K
- plus $10K from 31 others
What the payments were for
- Consulting fees$14,60023%
- Speaking & faculty fees$17,37527%
- Travel & lodging$8,89014%
- Food & beverage$21,87035%
- Education$5661%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 153 | $19,786 |
| Amgen(2 entities) | 163 | $12,476 |
| ANI Pharmaceuticals, Inc. | 66 | $7,025 |
| AstraZeneca(2 entities) | 110 | $5,694 |
| Johnson & Johnson | 73 | $5,251 |
| Kyowa Kirin, Inc. | 20 | $3,351 |
| Pfizer | 23 | $1,331 |
| Novartis | 45 | $1,087 |
| Eli Lilly | 1 | $1,050 |
| AbbVie | 62 | $1,036 |
| Lilly USA, LLC | 30 | $721 |
| Organon | 41 | $659 |
| GSK | 39 | $574 |
| Boehringer Ingelheim | 23 | $553 |
| Mallinckrodt Hospital Products Inc. | 18 | $448 |
| E.r. Squibb & Sons, L.L.C. | 10 | $393 |
| Aurinia Pharma U.S., Inc. | 13 | $328 |
| Janssen Scientific Affairs, LLC | 3 | $270 |
| Daiichi Sankyo Inc. | 9 | $216 |
| Fresenius Kabi USA, LLC | 14 | $216 |
| Genentech USA, Inc. | 10 | $172 |
| Sandoz | 7 | $160 |
| Actelion Pharmaceuticals US, Inc. | 6 | $129 |
| Radius Health, Inc. | 5 | $99 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Scilex Pharmaceuticals Inc. | 2 | $32 |
| Argenx US, Inc. | 1 | $31 |
| Pacira Pharmaceuticals Incorporated | 1 | $25 |
| Sanofi | 1 | $24 |
| Nalu Medical, Inc. | 1 | $20 |
| Pharmacosmos Therapeutics Inc. | 1 | $18 |
| Sobi, Inc | 1 | $17 |
| Tersera Therapeutics LLC | 1 | $16 |
| Celltrion USA Inc. | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| Octapharma USA, Inc. | 1 | $14 |
| Valinor Pharma, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$63,301 in reported general payments places this provider in the 95th percentile of 2,026 family providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CortrophinCorticotropin | 28 | $1,718,840 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 27 | $1,283,907 |
| RinvoqUpadacitinib | 101 | $667,207 |
| TremfyaGuselkumab | 34 | $463,779 |
| Taltz AutoinjectorIxekizumab | 67 | $454,463 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 54 | $449,218 |
| Humira(Cf) PenAdalimumab | 34 | $345,320 |
| Enbrel SureclickEtanercept | 45 | $332,061 |
| Cosentyx Sensoready PenSecukinumab | 21 | $219,568 |
| KevzaraSarilumab | 43 | $190,368 |
| Cosentyx Unoready PenSecukinumab | 13 | $134,212 |
| Cimzia (2 Pack)Certolizumab Pegol | 11 | $132,740 |
| EnbrelEtanercept | 11 | $93,090 |
| BenlystaBelimumab | 19 | $92,326 |
| Xeljanz XrTofacitinib Citrate | 16 | $89,826 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam | $1,331 | $1,283,90727 claims |
| AbbVieRinvoq | $1,036 | $667,207101 claims |
| Johnson & JohnsonTremfya | $5,251 | $463,77934 claims |
| SanofiKevzara | $24 | $190,36843 claims |
| UCB, Inc.Cimzia (2 Pack) | $19,786 | $132,74011 claims |
| AmgenEnbrel | $12,476 | $93,09011 claims |
| GSKBenlysta | $574 | $92,32619 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $32 | $9,51780 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,026 family providers in Oklahoma.
Other family in Oklahoma City
- April WilcoxOklahoma City$245K
- Samantha BellingerOklahoma City$39K
- Lacey HillOklahoma City$20K
- Julia John SamuelOklahoma City$17K
- Kristina SnyderOklahoma City$15K
- Lindi CiglarOklahoma City$15K
- Shymol JohnOklahoma City$14K
- Xiomara PorrasOklahoma City$12K
- Anne DudeOklahoma City$11K
- Kailee AndersonOklahoma City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.